Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabio Turco

Showing results (31-40 of 82) with videos related to

Pageof 9
Sort By:
United European Gastroenterology Journal|August 18, 2017
Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of <i>L. casei DG</i>® (<i>Lactobacillus paracasei</i> CNCM I-1572)Fabio Turco, Paolo Andreozzi, Ilaria Palumbo, et al.
Cells|February 15, 2022
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and BeyondAlessandro Audisio, Consuelo Buttigliero, Marco Donatello Delcuratolo, et al.
Endocrine-Related Cancer|May 5, 2021
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCCFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Cells|March 10, 2022
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to BedsideAntonio Ungaro, Marcello Tucci, Alessandro Audisio, et al.
Journal of Clinical Medicine|January 23, 2024
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell CarcinomaAlessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Cancer Treatment Reviews|May 9, 2024
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trialsMarcello Tucci, Marta Mandarà, Jacopo Giuliani, et al.
Critical Reviews in Oncology/Hematology|June 2, 2020
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectivesGianmarco Leone, Consuelo Buttigliero, Chiara Pisano, et al.
Cells|August 28, 2024
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective AnalysisGiovanni Farinea, Mariangela Calabrese, Federica Carfì, et al.
Prostate Cancer and Prostatic Diseases|December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysisFabio Turco, Silke Gillessen, Giorgio Treglia, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetateRosario F Di Stefano, Marcello Tucci, Fabio Turco, et al.
Pageof 9

Showing results (31-40 of 82) with videos related to

Sort By:
Pageof 9
United European Gastroenterology Journal|August 18, 2017
Bacterial stimuli activate nitric oxide colonic mucosal production in diverticular disease. Protective effects of <i>L. casei DG</i>® (<i>Lactobacillus paracasei</i> CNCM I-1572)Fabio Turco, Paolo Andreozzi, Ilaria Palumbo, et al.
Cells|February 15, 2022
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and BeyondAlessandro Audisio, Consuelo Buttigliero, Marco Donatello Delcuratolo, et al.
Endocrine-Related Cancer|May 5, 2021
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCCFabio Turco, Marcello Tucci, Rosario Francesco Di Stefano, et al.
Cells|March 10, 2022
Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to BedsideAntonio Ungaro, Marcello Tucci, Alessandro Audisio, et al.
Journal of Clinical Medicine|January 23, 2024
Navigating the ICI Combination Treatment Journey: Patterns of Response and Progression to First-Line ICI-Based Combination Treatment in Metastatic Renal Cell CarcinomaAlessandro Samuelly, Rosario Francesco Di Stefano, Fabio Turco, et al.
Cancer Treatment Reviews|May 9, 2024
Treatment options in first-line metastatic renal carcinoma: A meta-analysis of 2556 patients treated with immune checkpoint inhibitors-based combinations in randomised controlled trialsMarcello Tucci, Marta Mandarà, Jacopo Giuliani, et al.
Critical Reviews in Oncology/Hematology|June 2, 2020
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectivesGianmarco Leone, Consuelo Buttigliero, Chiara Pisano, et al.
Cells|August 28, 2024
Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective AnalysisGiovanni Farinea, Mariangela Calabrese, Federica Carfì, et al.
Prostate Cancer and Prostatic Diseases|December 14, 2023
Safety profile of darolutamide versus placebo: a systematic review and meta-analysisFabio Turco, Silke Gillessen, Giorgio Treglia, et al.
Prostate Cancer and Prostatic Diseases|February 19, 2021
Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetateRosario F Di Stefano, Marcello Tucci, Fabio Turco, et al.
Pageof 9